

1 **Topological data analysis identifies distinct biomarker phenotypes during the ‘inflammatory’ phase**  
2 **of COVID-19.**

3

4 **Authors:** Paul W. Blair, MD<sup>1,2\*</sup>, Joost Brandsma, PhD<sup>1</sup>, Josh Chenoweth, PhD<sup>1</sup>, Stephanie A. Richard,  
5 PhD<sup>3</sup>, Nusrat J. Epsi, PhD<sup>1,3</sup>, Rittal Mehta, MSc<sup>1</sup>, Deborah Striegel, PhD<sup>1</sup>, Emily G. Clemens, MFA<sup>2</sup>,  
6 David A. Lindholm, MD<sup>4,5</sup>, Ryan C. Maves, MD<sup>3,6,7</sup>; Derek T. Larson, DO<sup>8</sup>; Katrin Mende, MD<sup>3</sup>, Rhonda  
7 E. Colombo, MD<sup>1,3,9</sup>, Anuradha Ganesan, MD<sup>1,3,10</sup>, Tahaniyat Lalani, MD<sup>3,11</sup>, Christopher J Colombo,  
8 MD<sup>3,9</sup>, Allison A. Malloy, MD<sup>12</sup>, Andrew L. Snow, PhD<sup>13</sup>, Kevin L. Schully, PhD<sup>14</sup>, Charlotte Lanteri,  
9 PhD<sup>3</sup>, Mark P. Simons, PhD<sup>3,1</sup>, John S. Dumler, MD, PhD<sup>2</sup>, David Tribble, MD<sup>1,3</sup>, Timothy Burgess,  
10 MD<sup>4</sup>, Simon Pollett, MBBS<sup>1,3</sup>, Brian K. Agan, MD<sup>1,3</sup>, Danielle V. Clark, PhD<sup>1</sup> and the EPICC COVID-19  
11 Cohort Study Group.\*\*

12

13 **Affiliation:** <sup>1</sup>The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ,  
14 Bethesda, MD; <sup>2</sup>Department of Pathology, Uniformed Services University, Bethesda, MD; <sup>3</sup>Infectious  
15 Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed  
16 Services University, Bethesda, MD; <sup>4</sup>Department of Medicine, Uniformed Services University of the  
17 Health Sciences, Bethesda, MD; <sup>5</sup>Brooke Army Medical Center, Joint Base San Antonio-Ft Sam Houston,  
18 TX; <sup>6</sup>Departments of Internal Medicine and Anesthesiology, Wake Forest School of Medicine, Winston-  
19 Salem, North Carolina; <sup>7</sup>Naval Medical Center, San Diego, California; <sup>8</sup>Fort Belvoir Community Hospital,  
20 Fort Belvoir, VA; <sup>9</sup>Madigan Army Medical Center, Joint Base Lewis-McChord, WA; <sup>10</sup>Walter Reed  
21 National Military Medical Center, Bethesda, MD; <sup>11</sup>Naval Medical Center Portsmouth, Portsmouth, VA;  
22 <sup>12</sup>Department of Pediatrics, Uniformed Services University, Bethesda, MD; <sup>13</sup>Department of  
23 Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda, MD; <sup>14</sup>Biological  
24 Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD.

25 **\*Corresponding Author:** Paul W. Blair, MD MSPH MHS. Henry M. Jackson Foundation for the  
26 Advancement of Military Medicine. 6720A Rockledge Dr, Bethesda, MD 20817. E-mail: [pblair@aceso-  
sepsis.org](mailto:pblair@aceso-<br/>27 sepsis.org)

28 Reprints: Reprints are not being ordered for this manuscript.

29 Performance institution: Henry M. Jackson Foundation for the Advancement of Military Medicine

30 **Funding:** This project has been funded by the National Institute of Allergy and Infectious Diseases,  
31 National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072, the Defense Health Program,  
32 U.S. DoD, under award HU0001190002, and the Defense Health Agency, U.S. DoD, under awards  
33 HU00012020070 and W911QY-20-9-0006. Biomarker assay reagents and analysis support was  
34 provided by JPEO W911QY-20-9-0004 (2020 OTA).

35  
36

37 **Word count:** 2,995

38 **Abstract Word count:** 225

39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

62 **Abstract:**

63 **OBJECTIVES:** The relationships between baseline clinical phenotypes and the cytokine milieu of the peak  
64 ‘inflammatory’ phase of coronavirus 2019 (COVID-19) are not yet well understood. We used Topological  
65 Data Analysis (TDA), a dimensionality reduction technique to identify patterns of inflammation associated  
66 with COVID-19 severity and clinical characteristics.

67 **DESIGN:** Exploratory analysis from a multi-center prospective cohort study.

68 **SETTING:** Eight military hospitals across the United States between April 2020 and January 2021.

69 **PATIENTS:** Adult ( $\geq 18$  years of age) SARS-CoV-2 positive inpatient and outpatient participants were  
70 enrolled with plasma samples selected from the putative ‘inflammatory’ phase of COVID-19, defined as  
71 15-28 days post symptom onset.

72 **INTERVENTIONS:** None.

73 **MEASUREMENTS AND MAIN RESULTS:** Concentrations of 12 inflammatory protein biomarkers were  
74 measured using a broad dynamic range immunoassay. TDA identified 3 distinct inflammatory protein  
75 expression clusters. Peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity  
76 Index (CCI), and body mass index (BMI) were evaluated with logistic regression for associations with each  
77 cluster. The study population (n=129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31  
78 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct clusters were found that differed by peak disease  
79 severity (p <0.001), age (p <0.001), BMI (p<0.001), and CCI (p=0.001).

80 **CONCLUSIONS:** Exploratory clustering methods can stratify heterogeneous patient populations and  
81 identify distinct inflammation patterns associated with comorbid disease, obesity, and severe illness due to  
82 COVID-19.

83 **KEY WORDS:** COVID-19; SARS-CoV-2; Topological Data Analysis; Coronavirus Infections /  
84 immunology, Cytokines / analysis

85

86

87

88 **Background**

89 While clinical risk factors for coronavirus disease 2019 (COVID-19) severity have been described,  
90 mechanisms of inflammation associated with these baseline clinical features are less understood (1). SARS-  
91 CoV-2 infections range from asymptomatic to fatal illness. This spectrum is associated with host risk factors  
92 such as age and chronic noncommunicable disease (NCD), including obesity and cardiovascular disease  
93 (2). However, the pathways from host factors to COVID-19 severity and sequelae are largely unknown.  
94 Given the heterogeneity of COVID-19 severity and a growing immunomodulatory treatment  
95 armamentarium (2, 3), pathologic inflammation patterns and their association with comorbidities need to  
96 be identified to optimize treatment selection.

97

98 COVID-19 severity and inflammation occur in three phases: acute, inflammatory, and late phases of illness.  
99 Peak severity and peak inflammatory biomarkers generally occur after two weeks of illness (15 to 28 days  
100 after symptom onset) during the inflammatory phase (4, 5). While inflammation may subside in mild cases,  
101 persistently high proinflammatory cytokines have been noted in more severe cases during this period. This  
102 time window of heightened immune response may be best suited to elucidate the relationship between host  
103 factors and severe COVID-19. *In silico* stratification of host-biomarker profiles using exploratory clustering  
104 and machine learning analyses has the potential to identify distinct phenotypes associated with disease  
105 severity, which in turn can lead to discovery of personalized treatment approaches.

106

107 Herein we define inflammatory host-biomarker phenotypes of COVID-19 identified by Topological Data  
108 Analysis (TDA) and their associated comorbid conditions and disease severity. TDA is a multivariate  
109 pattern analytical tool that uses an unsupervised approach to dimensionality reduction and data visualization  
110 (6). TDA can be used to identify biomarker patterns and phenotype-biomarker relationships (7-9). TDA has  
111 been demonstrated to identify patient subgroups that would benefit from personalized interventions for  
112 heterogeneous diseases such as cancer care and primary ciliary dyskinesia (6, 8). We hypothesized that the  
113 network approach of TDA clustering would identify unique inflammation phenotype patterns associated

114 with severity, demographics, and co-morbid conditions known to predispose patients to worse outcomes  
115 during SARS-CoV-2 infection (4). Our analysis focused on samples collected during the inflammatory  
116 phase from an observational cohort of participants with mild to severe COVID-19 at military treatment  
117 facilities. Inflammatory biomarkers were selected from prior unpublished non-COVID-19 sepsis TDA  
118 analyses (10) and from clinical use (11). We sought to demonstrate that this analytical approach can help  
119 discern inflammatory patterns to find possible treatment targets, as well as serve as a tool to understand  
120 baseline host factors and severe COVID-19.

121

## 122 **Methods**

123 Participants were enrolled in a prospective, multi-center COVID-19 cohort under the Epidemiology,  
124 Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential  
125 (EPICC) protocol, at 8 military treatment facilities (Brooke Army Medical Center, San Antonio, TX; Fort  
126 Belvoir Community Hospital, Fort Belvoir, VA; Madigan Army Medical Center, Joint Base Lewis-  
127 McChord, WA; Naval Medical Center Portsmouth, Portsmouth, VA; Naval Medical Center San Diego, San  
128 Diego, CA; Tripler Army Medical Center, Honolulu, HI; William Beaumont Army Medical Center, El  
129 Paso, TX; Walter Reed National Military Medical Center, Bethesda, MD) between April 2020 and January  
130 2021 (12). The protocol was approved by the Uniformed Services University Institutional Review Board  
131 (IDCRP-085)(13). All patients provided written informed consent. EPICC study enrollment included  
132 subjects  $\geq 18$  years of age with laboratory-confirmed or suspected SARS-CoV-2 infection seeking inpatient  
133 or outpatient medical care. Following consent, demographic, comorbidity, and illness data were collected  
134 through participant interviews and a review of the participant's electronic medical record or using  
135 participant completed surveys implemented in November 2020. Subjects with a positive clinical SARS-  
136 CoV-2 RT-PCR result and plasma samples collected were included in this analysis. Results of well-  
137 described (14) COVID-19 clinical biomarkers CRP, ferritin, and IL-6, were explored from 249 participants  
138 with plasma collected 0-29 days post symptom onset (dps) to determine if the longitudinal inflammatory  
139 biomarker LOESS (locally estimated scatterplot smoothing) curve peaked between 14 to 28 days per

140 previously published phases of illness framework for studying COVID-19 (Supplementary Figure S1) (4).  
141 These trends were consistent with the literature, and, accordingly, the TDA was restricted to the 129  
142 participants with samples collected during the inflammatory phase defined as 15-28 dps. Receipt of  
143 baricitinib, tocilizumab, hydroxychloroquine, or systemic steroids (equivalent to prednisone 10mg daily or  
144 above) at the time of blood collection was determined through the electronic medical record or participant  
145 surveys.

146  
147 Plasma samples were prospectively collected after enrollment as previously described (13). Venous whole  
148 blood samples were centrifuged for 10 minutes at 1500 g and collected plasma was stored at  $-80^{\circ}\text{C}$ . A  
149 panel of 12 inflammatory proteins were measured in the plasma samples using the high dynamic range  
150 automated enzyme-linked immunosorbent assay Ella microfluidic analyzer (ProteinSimple, San Jose,  
151 California, USA). The panel included: IL-6, CXCL10, IL-1RA, D-dimer, procalcitonin, ferritin, VEGF-A,  
152 IL-5, soluble receptor for advanced glycation end-product (RAGE), TNFR1, IFN- $\gamma$ , and C-reactive protein  
153 (CRP). This panel was selected to include analytes in clinical use for prognostication (i.e., CRP,  
154 procalcitonin, ferritin, and D-dimer)(11), based on prior COVID-19 literature (i.e., IL-6, IFN- $\gamma$  and  
155 CXCL10) (15), and identified to be representative of prior TDA-based non-COVID-19 sepsis clusters (i.e.,  
156 IL-1RA, VEGF-A, IL-5, RAGE, and TNFR1) (10, 16). All protein concentrations were  $\log_{10}$ -transformed  
157 and normalized for site-to-site variation using the *R* package *SVA ComBat* (17). A small number (1.6%) of  
158 missing values were imputed using a *k*-nearest neighbor model, and out-of-range values were imputed using  
159 either the lowest or highest measured value within range of the Ella platform. Correlation between analytes  
160 was explored with a principal component analysis and determining the Spearman's correlation coefficients.  
161 For some subjects, multiple samples were available. In such cases, the sample with the highest coefficient  
162 of variation across all analytes was retained to incorporate the largest degree of relative variability at that  
163 time point (18).

164

165 Protein expression networks were generated solely using biomarkers levels with the TDA “Mapper”  
166 algorithm using the EurekaAI platform (SymphonyAI, Los Altos, CA, USA)(7, 19, 20). TDA networks  
167 were generated for a range of resolution settings to examine the persistence of subject clusters and their  
168 interrelatedness. Peaked severity (outpatient, hospitalized, ICU-level or death) color gradients were  
169 overlaid on identified clusters. Levels of the individual proteins in each TDA group were summarized in a  
170 series of boxplots (*R* package “ggplot2” v3.3.5). Backward selection stepwise logistic regression using a  
171 Bernoulli-adjusted significance level of 0.0042 (i.e., 0.05/12) was used to identify which proteins were up-  
172 or downregulated within each cluster. While TDA clusters will inherently have different biomarker levels,  
173 this was performed to simplify inference about representative biomarkers and for future validation in  
174 external cohorts. A sensitivity analysis was performed adjusting for peak severity to determine the effect  
175 of covariate selection. An additional sensitivity analysis was performed excluding participants receiving  
176 systemic steroids.

177  
178 Summary statistics were calculated for the TDA clusters, comparing baseline demographics (e.g., sex, age,  
179 race, ethnicity, selected medical comorbidities), days post symptom onset, peak severity, steroid use, and  
180 the inflammatory biomarkers by clusters using either Chi-square (categorical values), Fisher exact  
181 (categorical values), or Mann-Whitney U tests (continuous values). Charlson Comorbidity Index (CCI) and  
182 body mass index (BMI) values were divided into score-based categories (i.e., CCI: 0, 1-2, 3-4, or 5+; BMI:  
183  $<30$ , 30-39.9, or  $\geq 40$  kg/m<sup>2</sup>) to describe the prevalence of comorbid conditions by cluster on a bar plot but  
184 were otherwise treated as continuous values. BMI values were not available from 6.2% of the cohort. Peak  
185 severity was categorized for each participant (outpatient, non-ICU [intensive care unit] inpatient, and ICU  
186 or death). Multivariable logistic regression adjusting for peak severity was used to identify associations  
187 between each TDA cluster and BMI or CCI at a significance level of 0.05. All statistical analyses were  
188 performed in Stata (version 15.0; StataCorp LLC, College Station, TX, USA) and R version 4.0.2 (21)

189

## 190 **Results**

191 Biomarkers CRP, IL-6, and ferritin were stratified by severity and explored for the 249 participants in the  
192 EPICC cohort between 0-28 dpso using a scatter plot with LOESS (locally estimated scatterplot smoothing)  
193 curves. This demonstrated average cytokines peaked or remained elevated during the described  
194 inflammatory phase (15-28 dpso) among ICU-level or fatal courses of illness (Supplementary Figure S1).  
195 Based on these findings and the inflammatory phase literature, we restricted our analysis to 129 participants  
196 (66.7% male, median 41.3 years of age) including 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal  
197 cases (Table 1) between 15 to 28 days of illness. Correlation along a PCA axis was observed among  
198 procalcitonin, TNFR1, IL-6, CRP, and IL-1RA while RAGE, IFN- $\gamma$ , IL-5, and VEGF-A were less  
199 correlated with the other analytes. Additionally, variance increased with each level of peak severity  
200 (Supplementary Figure S2). These results supported the additive information provided by the 12 protein  
201 analytes, and TDA was performed. Interestingly, 3 distinct inflammatory proteins clusters, labeled Cluster  
202 1, Cluster 2, and Cluster 3 (Figure 1; Supplementary Figure S3), were consistently identified using TDA.  
203  
204 Age differed significantly between TDA clusters ( $p < 0.001$ ). Participants from TDA Clusters 2 (median  
205 37.1 years of age; IQR, 28.1 to 50.0) and 3 (median 36.3 years of age; IQR, 24.6 to 55.2) were younger  
206 than in Cluster 1 (median 51.8 years of age; IQR, 37.3 to 65.0) (Table 1). The prevalence of male gender  
207 was similar among Cluster 1 (62.0%,  $n=31$ ), Cluster 2 (64.1%,  $n=41$ ), and the general cohort (66.7%), but  
208 cluster 3 was predominantly male (93.3%,  $n=14$ ). The median time from symptom onset to sample  
209 collection was 21 days (IQR 18 to 25) and did not differ between clusters (Table 1). Peak disease severity,  
210 as categorized by hospitalization status, was also found to differ significantly among the TDA clusters  
211 ( $p < 0.001$ ). Cluster 1 had the highest prevalence of severe COVID-19, comprising 66.0% ( $n=33$ )  
212 hospitalized participants, compared to 46.7% ( $n=7$ ) hospitalized participants in Cluster 3, and 18.8% ( $n=12$ )  
213 hospitalized participants in Cluster 2 (Figure 2, Table 1). All fatal cases ( $n=5$ ) were in Cluster 1. No  
214 individuals had received baricitinib or tocilizumab, and hydroxychloroquine use was limited to 2  
215 individuals in Cluster 1. Receipt of systemic steroids at the time of blood collection was limited to 5  
216 participants in Cluster 1 (10.0%;  $n=5$ ).



217

218 The median CCI differed ( $p=0.009$ ) among clusters ranging from 2 (IQR, 2 to 3) in Cluster 1 to 0 (IQR 0  
219 to 0.5) in Cluster 2 and 0 (IQR, 0 to 1) in Cluster 3. Most participants in Cluster 2 (75.0%) and in Cluster 3  
220 (73.3%) had a CCI of 0 compared to 38.0% of individuals in Cluster 1 (Figure 2). Additionally, median  
221 BMI was higher in Cluster 1 (33.5 kg/m<sup>2</sup>; IQR, 29.0 to 37.0) compared to in Cluster 2 and Cluster 3, which  
222 were the same (28.0 kg/m<sup>2</sup>; IQR, 25.0 to 31.0)(Table 1). After adjusting for peak severity using logistic  
223 regression, participants with a higher BMI (OR: 1.1 per kg/m<sup>2</sup>,  $p=0.002$ ) and a higher CCI (OR: 1.3 for  
224 each score increase,  $p=0.02$ ) were more common in Cluster 1 compared to participants in Cluster 2 and 3  
225 combined.

226

227 In summary, participants in Cluster 1 were more likely to be older, have higher BMI and more  
228 comorbidities, and have more severe disease, whereas participants in Cluster 2 were more likely to be  
229 younger, have lower BMI and comorbidities, and have mild illness (Figure 2). Cluster 3 was predominantly  
230 composed of younger adult predominantly male participants, without comorbid conditions, among whom  
231 almost half (7 of 15) were hospitalized.

232

233 The distributions of each analyte were different across clusters using a chi-squared test, except for IL-5 and  
234 IFN- $\gamma$  which had a similar distribution (Table 2). Certain biomarkers including CRP, IL-6, IL-1RA, D-  
235 dimer, TNFR1, and VEGF-A were more elevated in Cluster 1 (older participants with higher severity)  
236 compared to Clusters 2 and 3 (Table 2; Figure 3; Supplementary Figure 4). RAGE was lower in Cluster 1  
237 compared to Clusters 2 or 3 and IFN- $\gamma$  was lower in Cluster 1 compared to Cluster 2 (Figure 3;  
238 Supplementary Figure 4). Cluster 3, a young cluster with moderate severity, was found to have higher  
239 ferritin, procalcitonin, and CXCL10, and lower VEGF-A compared to Cluster 2, a similarly young cluster  
240 with mild illness.

241

242 Stepwise regression, both unadjusted and adjusted for peak severity, was used to identify which analytes  
243 were most characteristic of each TDA cluster (Supplementary Table S1.). The distinguishing biomarker of  
244 Cluster 1 were relatively high IL-1RA and low RAGE levels; these subjects had a high severity phenotype  
245 compared to other clusters (Figure 3; Supplementary Figure 4; Supplementary Table S1.). Regardless of  
246 peak severity, Cluster 2 was characterized by relatively low procalcitonin and high RAGE levels. Cluster 3  
247 was characterized by low VEGF-A after peak severity adjustment (Figure 3; Supplementary Figure 4;  
248 Supplementary Table S1.). When restricting the analysis to those not receiving steroids, the models were  
249 qualitatively unchanged, and the same covariates were selected.

250

## 251 **Discussion**

252 We demonstrated that a multi-site prospective patient cohort can be stratified into three distinct  
253 inflammatory profiles using 12 protein biomarkers from samples collected during the inflammatory phase  
254 of COVID-19. TDA dimensionality reduction was able to identify biomarker patterns with differences in  
255 both severity and comorbid conditions between cluster phenotypes. Combinations of biomarkers,  
256 independent of clinical information, grouped participants into one of three distinct clusters: high COVID-  
257 19 severity, older, with comorbid conditions (Cluster 1); low severity, younger, less comorbid illness  
258 (Cluster 2); and a moderate severity, younger, previously healthy, male-predominant group (Cluster 3).  
259 This proof-of-concept study identifies potential use of TDA as a strategy to identify biomarker clusters  
260 associated with the heterogeneity of COVID-19 clinical presentations. Whilst exploratory, this reveals  
261 potential translational approaches to using host-biomarker stratification with advanced clustering and  
262 network analytical techniques, such as TDA, to better understand what drives phenotypic differences in the  
263 clinical presentation of COVID-19.

264

265 Patterns of inflammation observed for the different TDA clusters could suggest dysregulated pathways  
266 associated with COVID-19 pathology. Cluster 1 was found to be the highest severity cluster with all fatal  
267 cases and most ICU-level cases. This cluster contained distinctly more subjects with baseline comorbid

268 conditions and obesity as defined by BMI  $\geq$ 30. Cluster 1 subjects had higher IL-1RA compared to Cluster  
269 2 and 3, clusters represented by participants with less comorbid conditions. Consistent with this trend, prior  
270 work has identified IL-1RA as a potential mediator between obesity and COVID-19 severity (22).  
271 Interestingly, IFN- $\gamma$  was lower and IL-6 higher in Cluster 1 compared to the Cluster 2 participants. This  
272 pattern of an aberrant Th1 response has been previously identified to be associated with severe COVID-19  
273 and potentially distinct from influenza infection (22). Cluster 1 aligned with baseline comorbid illnesses  
274 known to be risk factors for severe COVID-19 with potentially distinct inflammatory cascade patterns  
275 demonstrated.

276

277 Cluster 3 was unique in that it had a combination of low VEGF-A but had elevated ferritin and higher  
278 prevalence of severe illness compared to Cluster 2, a mild illness cluster with comparable demographics.  
279 While sample size is limited, 14 of 15 participants in Cluster 3 were male, suggestive of a biologic sex  
280 difference in immune response among these previously healthy young men. Sex differences leading to  
281 severe COVID-19 among men have been previously described with X-linked TLR7 deficiency(23, 24)  
282 and on a larger scale with sex-related differences in innate and T-cell responses (25). A combination of  
283 low VEGF-A and elevated ferritin may identify a unique inflammation subtype and merits further study  
284 with external cohorts.

285

286 RAGE, a biomarker of acute lung injury (26), was found to have different distributions between clusters.  
287 In contrast to prior research (27), RAGE levels appeared to be higher among the younger and relatively  
288 milder COVID-19 severity Cluster 2 compared to Cluster 1. Compared to other clusters, RAGE was  
289 elevated along with IFN- $\gamma$  in the less symptomatic Cluster 2, but with lower acute phase reactants ferritin  
290 and procalcitonin. The converse was true with Cluster 1 where lower levels of RAGE in individuals were  
291 noted, along with elevated acute phase reactants (i.e., CRP, procalcitonin, and ferritin). This association  
292 of lower RAGE with higher severity Clusters 1 and 3 contrasts with a direct association with COVID-19  
293 mortality (28). However, our results may differ by accounting for biomarker patterns rather than

294 evaluating each biomarker in isolation. It is possible that RAGE could be an indicator of severity during  
295 certain disease states but functioning as an adaptive anti-inflammatory protein in Cluster 2 during the  
296 inflammatory phase. Soluble RAGE has been shown to reduce vascular injury in rodent models (29, 30)  
297 and could be protective against vascular inflammation mediated the RAGE receptor (31). The  
298 paradoxically inverse relationship observed between RAGE and these commonly used acute phase  
299 reactants between the clusters could be useful for identification and stratification of individuals with  
300 COVID-19.

301

302 While this study, to our knowledge, is the first to use an advanced dimensionality reduction approach to  
303 understand relationships between biomarker patterns and clinical phenotypes during the inflammatory  
304 phase of COVID-19, there are limitations worth noting. Samples were collected from April 2020 to  
305 January 2021 and treatment practices and epidemiologic changes over time may have affected  
306 inflammation patterns. Hence, we incorporated a sensitivity analysis excluding those that received  
307 systemic steroids in Cluster 1 to aid in interpreting the findings. In addition, the sample size may limit our  
308 ability to identify uncommon biomarker patterns and external validation is needed of patterns identified.  
309 Additionally, regression was used to adjust for peak severity to identify biomarker and comorbid  
310 condition associations with TDA clusters distinct from severity trajectory differences. While this is a  
311 novel feature of this biomarker study, residual confounding related to peak severity remains possible.  
312 Despite limitations, results presented here are hypothesis generating and should be evaluated further in  
313 additional cohorts.

314

315 This approach constitutes an early exploratory step in identifying host biomarker patterns that may be  
316 leveraged for personalized interventions, and offers new insights for COVID19 prognosis, therapy, and  
317 prevention with techniques that could be extended to understanding other severe infections. Using analytes  
318 identified from our international sepsis cohort research(10), 3 biomarker clusters with different phenotypic  
319 associations were identified among those with heterogenous COVID-19 presentations. The application of

320 these biomarkers derived from non-COVID-19 severe infection research suggests that pathogen-agnostic  
321 sepsis biomarkers could be identified for personalized approaches to triage of care or immunomodulation  
322 strategies. Further validation of these markers and clustering algorithms with external cohorts could inform  
323 point-of-care biomarker assay development to guide more individualized approaches to COVID-19 care.

324

325 **Acknowledgements:**

326 \*\*We thank the members of the EPICC COVID-19 Cohort Study Group for their many contributions in  
327 conducting the study and ensuring effective protocol operations. The following members were all closely  
328 involved with the design, implementation, and/or oversight of the study and have met group authorship  
329 criteria for this manuscript:

330 *Brooke Army Medical Center, Fort Sam Houston, TX:* Col J. Cowden; LTC M. Darling; T. Merritt; CPT  
331 T. Wellington

332 *Fort Belvoir Community Hospital, Fort Belvoir, VA:* A. Rutt

333 *Madigan Army Medical Center, Joint Base Lewis McChord, WA:* CAPT C. Conlon; COL P. Faestel;  
334 COL C. Mount

335 *Naval Medical Center Portsmouth, Portsmouth, VA:* LCDR A. Smith; R. Tant; T. Warkentien

336 *Naval Medical Center San Diego, San Diego, CA:* CDR C. Berjohn; CAPT (Ret) G. Utz

337 *Tripler Army Medical Center, Honolulu, HI:* LTC C. Madar; C. Uyehara

338 *Uniformed Services University of the Health Sciences, Bethesda, MD:* K Chung; C. English; C. Fox; M.  
339 Grother; COL P. Hickey; E. Laing; LTC J. Livezey; E. Parmelee; J. Rozman; M. Sanchez; A. Scher

340 *United States Air Force School of Aerospace Medicine, Dayton, OH:* Sgt T. Chao; R. Chapleau; A. Fries;  
341 K. Reynolds

342 *Womack Army Medical Center, Fort Bragg, NC:* LTC D. Hostler; LTC J. Hostler; MAJ K. Lago; C.  
343 Maldonado

344 *William Beaumont Army Medical Center, El Paso, TX:* MAJ T. Hunter; R. Mody; M. Wayman

345 *Walter Reed National Military Medical Center, Bethesda, MD:* MAJ N. Huprikar  
346  
347 The authors wish to also acknowledge all who have contributed to the EPICC COVID-19 study:  
348 *Brooke Army Medical Center, Fort Sam Houston, TX:* Col J. Cowden; LTC M. Darling; S.  
349 DeLeon; Maj D. Lindholm; LTC A. Markelz; K. Mende; S. Merritt; T. Merritt; LTC N. Turner; CPT T.  
350 Wellington  
351 *Carl R. Darnall Army Medical Center, Fort Hood, TX:* LTC S. Bazan; P.K Love  
352 *Fort Belvoir Community Hospital, Fort Belvoir, VA:* N. Dimascio-Johnson; MAJ E. Ewers; LCDR K.  
353 Gallagher; LCDR D. Larson; A. Rutt  
354 *Henry M. Jackson Foundation, Inc., Bethesda, MD:* P. Blair; J. Chenoweth; D. Clark  
355 *Madigan Army Medical Center, Joint Base Lewis McChord, WA:* S. Chambers; LTC C. J. Colombo; R.  
356 Colombo; CAPT C. Conlon; CAPT K. Everson; COL P. Faestel; COL T. Ferguson; MAJ L. Gordon;  
357 LTC S. Grogan; CAPT S. Lis; COL C. Mount; LTC D. Musfeldt; CPT D. Odineal; LTC M. Perreault; W.  
358 Robb-McGrath; MAJ R. Sainato; C. Schofield; COL C. Skinner; M. Stein; MAJ M. Switzer; MAJ M.  
359 Timlin; MAJ S. Wood  
360 *Naval Medical Center Portsmouth, Portsmouth, VA:* S. Banks; R. Carpenter; L. Kim; CAPT  
361 K. Kronmann; T. Lalani; LCDR T. Lee; LCDR A. Smith; R. Smith; R. Tant; T. Warkentien  
362 *Naval Medical Center San Diego, San Diego, CA:* CDR C. Berjohn; S. Cammarata; N.  
363 Kirkland; CAPT (Ret) R. Maves; CAPT (Ret) G. Utz  
364 *Tripler Army Medical Center, Honolulu, HI:* S. Chi; LTC R. Flanagan; MAJ M. Jones; C. Lucas; LTC C.  
365 Madar; K. Miyasato; C. Uyehara  
366 *Uniformed Services University of the Health Sciences, Bethesda, MD:* B. Agan; L. Andronescu; A.  
367 Austin; C. Broder; CAPT T. Burgess; C. Byrne; COL K Chung; J. Davies; C. English; N. Epsi; C.  
368 Fox; M. Fritschlanski; M. Grother; A. Hadley; COL P. Hickey; E. Laing; LTC C. Lanteri; LTC  
369 J. Livezey; A. Malloy; R. Mohammed; C. Morales; P. Nwachukwu; C. Olsen; E. Parmelee; S. Pollett; S.

370 Richard; J. Rozman; J. Rusiecki; E. Samuels; M. Sanchez; A. Scher; CDR M. Simons; A.  
371 Snow; K. Telu; D. Tribble; L. Ulomi  
372 *United States Air Force School of Medicine, Dayton, OH:* Sgt T. Chao; R. Chapleau; A. Fries; C.  
373 Harrington; S. Huntsberger; S. Purves; K. Reynolds; J. Rodriguez; C. Starr  
374 *Womack Army Medical Center, Fort Bragg, NC:* B. Barton; LTC D. Hostler; LTC (Ret) J. Hostler; MAJ  
375 K. Lago; C. Maldonado; J. Mehrer  
376 *William Beaumont Army Medical Center, El Paso, TX:* MAJ T. Hunter; J. Mejia; R. Mody; R.  
377 Resendez; P. Sandoval; M. Wayman  
378 *Walter Reed National Military Medical Center, Bethesda, MD:* I. Barahona; A. Baya; A. Ganesan;  
379 MAJ N. Huprikar; B. Johnson  
380 *Walter Reed Army Institute of Research, Silver Spring, MD:* S. Peel  
381

382 **Conflicts of Interest:** S. D. P., M.P.S., T. H. B, and D.R.T. report that the Uniformed Services University  
383 (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution,  
384 and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc (HJF) were funded  
385 under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19  
386 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU  
387 IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical,  
388 Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine  
389 trial sponsored by AstraZeneca. Both of these trials were part of the US Government COVID-19 response.  
390 Neither is related to the work presented here.

391  
392 **Disclaimer:** The contents of this article are the sole responsibility of the authors and do not necessarily  
393 reflect the views, assertions, opinions, or policies of the Henry M. Jackson Foundation for the Advancement  
394 of Military Medicine, Inc., the U.S. Department of Defense, the U.S. government, or any other government  
395 or agency. Mention of trade names, commercial products, or organizations does not imply endorsement by

396 the U.S. government. Some of the authors of this work are military service members or employees of the  
397 U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. x105 provides that  
398 “Copyright protection under this title is not available for any work of the United States government.” Title  
399 17 U.S.C. x101 defines a U.S. government work as a work prepared by a military service member or  
400 employee of the U.S. government as part of that person’s official duties. The investigators have adhered to  
401 the policies for protection of human subjects as prescribed in 45 CFR 46. This research has been approved  
402 the USU Institutional Review Board in compliance with all applicable federal regulations governing the  
403 protection of human subjects.

404

#### 405 **References**

- 406 1. Buicu AL, Cernea S, Benedek I, et al: Systemic Inflammation and COVID-19 Mortality in  
407 Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity. *J*  
408 *Clin Med* 2021; 10(8)
- 409 2. Cummings MJ, Baldwin MR, Abrams D, et al: Epidemiology, clinical course, and outcomes of  
410 critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;  
411 395(10239):1763-1770
- 412 3. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,  
413 controlled, open-label, platform trial. *Lancet* 2021; 397(10285):1637-1645
- 414 4. Datta SD, Talwar A, Lee JT: A Proposed Framework and Timeline of the Spectrum of Disease  
415 Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *JAMA*  
416 2020; 324(22):2251-2252
- 417 5. Cevik M, Kuppalli K, Kindrachuk J, et al: Virology, transmission, and pathogenesis of SARS-  
418 CoV-2. *Bmj* 2020; 371:m3862
- 419 6. Nicolau M, Levine AJ, Carlsson G: Topology based data analysis identifies a subgroup of breast  
420 cancers with a unique mutational profile and excellent survival. *Proc Natl Acad Sci U S A* 2011;  
421 108(17):7265-7270



- 422 7. Singh G, Mémoli F, Carlsson GE: Topological methods for the analysis of high dimensional data  
423 sets and 3d object recognition. *PBG@ Eurographics 2007*; 2
- 424 8. Shoemark A, Rubbo B, Legendre M, et al: Topological data analysis reveals genotype-phenotype  
425 relationships in primary ciliary dyskinesia. *Eur Respir J 2021*; 58(2)
- 426 9. Bruno JL, Romano D, Mazaika P, et al: Longitudinal identification of clinically distinct  
427 neurophenotypes in young children with fragile X syndrome. *Proceedings of the National Academy of*  
428 *Sciences 2017*; 114(40):10767-10772
- 429 10. Krishnan S, Beckett C, Espinosa B, et al: Austere environments Consortium for Enhanced Sepsis  
430 Outcomes (ACESO). *Shock (Augusta, Ga) 2020*; 53(3):377-378
- 431 11. Cihakova D, Streiff MB, Menez SP, et al: High-value laboratory testing for hospitalized COVID-  
432 19 patients: a review. *Future Virol 2021*
- 433 12. Laing E, Sterling S, Richard S, et al: A betacoronavirus multiplex microsphere immunoassay  
434 detects early SARS-CoV-2 seroconversion and antibody cross reactions. *Res Sq 2020*
- 435 13. Richard SA, Pollett SD, Lanteri CA, et al: COVID-19 outcomes among U.S. Military Health  
436 System beneficiaries include complications across multiple organ systems and substantial functional  
437 impairment. *Open Forum Infectious Diseases 2021*
- 438 14. Gustine JN, Jones D: Immunopathology of Hyperinflammation in COVID-19. *Am J Pathol 2021*;  
439 191(1):4-17
- 440 15. Lucas C, Wong P, Klein J, et al: Longitudinal analyses reveal immunological misfiring in severe  
441 COVID-19. *Nature 2020*
- 442 16. Rozo M, Schully KL, Philipson C, et al: An Observational Study of Sepsis in Takeo Province  
443 Cambodia: An in-depth examination of pathogens causing severe infections. *PLoS Negl Trop Dis 2020*;  
444 14(8):e0008381
- 445 17. Leek JT, Johnson WE, Parker HS, et al: The sva package for removing batch effects and other  
446 unwanted variation in high-throughput experiments. *Bioinformatics 2012*; 28(6):882-883

- 447 18. Epsi NJ, Panja S, Pine SR, et al: pathCHEMO, a generalizable computational framework  
448 uncovers molecular pathways of chemoresistance in lung adenocarcinoma. *Communications Biology*  
449 2019; 2(1):334
- 450 19. Ayasdi. Available at: <https://www.ayasdi.com/enterprise-ai/platform/>. Accessed
- 451 20. Lum PY, Singh G, Lehman A, et al: Extracting insights from the shape of complex data using  
452 topology. *Sci Rep* 2013; 3:1236
- 453 21. Team TRDC: R: A language environment for statistical computing. R Foundation for Statistical  
454 Computing. 2020
- 455 22. Karaba AH, Zhou W, Hsieh LL, et al: Differential Cytokine Signatures of SARS-CoV-2 and  
456 Influenza Infection Highlight Key Differences in Pathobiology. *Clin Infect Dis* 2021
- 457 23. van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al: Presence of Genetic Variants Among  
458 Young Men With Severe COVID-19. *Jama* 2020; 324(7):663-673
- 459 24. Asano T, Boisson B, Onodi F, et al: X-linked recessive TLR7 deficiency in ~1% of men under 60  
460 years old with life-threatening COVID-19. *Sci Immunol* 2021; 6(62)
- 461 25. Takahashi T, Ellingson MK, Wong P, et al: Sex differences in immune responses that underlie  
462 COVID-19 disease outcomes. *Nature* 2020; 588(7837):315-320
- 463 26. Griffiths MJD, McAuley DF: RAGE: a biomarker for acute lung injury. *Thorax* 2008;  
464 63(12):1034-1036
- 465 27. Lim A, Radujkovic A, Weigand MA, et al: Soluble receptor for advanced glycation end products  
466 (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical  
467 ventilation, ARDS and mortality. *Ann Intensive Care* 2021; 11(1):50
- 468 28. Abers MS, Delmonte OM, Ricotta EE, et al: An immune-based biomarker signature is associated  
469 with mortality in COVID-19 patients. *JCI Insight* 2021; 6(1)
- 470 29. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al: Receptor for advanced-glycation end  
471 products: key modulator of myocardial ischemic injury. *Circulation* 2006; 113(9):1226-1234

- 472 30. Wendt T, Harja E, Bucciarelli L, et al: RAGE modulates vascular inflammation and  
473 atherosclerosis in a murine model of type 2 diabetes. *Atherosclerosis* 2006; 185(1):70-77
- 474 31. Harja E, Bu DX, Hudson BI, et al: Vascular and inflammatory stresses mediate atherosclerosis  
475 via RAGE and its ligands in apoE<sup>-/-</sup> mice. *J Clin Invest* 2008; 118(1):183-194

476

477 **Figure legends.**

478 **Figure 1.** Topological data analysis (TDA) network of protein expression during the middle-phase of  
479 COVID-19. Distinct protein expression phenotypes (Clusters 1, 2, and 3) were identified based on density  
480 and break points in the network and persistence of the clusters. Each node represents a combination of 12  
481 plasma protein analyte levels and its size increases with the number of participants that are included.  
482 Edges (lines between nodes) indicate that patients are represented in more than one node. The network is  
483 colored by the average score on the disease severity scale (from outpatients without limitations [green] to  
484 death [red]) in each node. Analysis was performed on the EurekaAI Workbench (SymphonyAI, Los  
485 Altos, CA, USA).

486

487 **Figure 2.** Cluster differences with bar plots (% [n]) of comorbid diseases and severity by cluster. A: BMI  
488 (body mass index) category (range in kg/m<sup>2</sup>) prevalence by cluster; B: Charlson Comorbidity Index (CCI)  
489 category prevalence by cluster; C: peak levels of severity by cluster. Total (n) presented in the center of  
490 each category.

491

492 **Figure 3.** Box plots of markers selected in stepwise regression to identify characteristic biomarkers of  
493 each cluster: Ferritin (A), IL1RA (B), RAGE (C), and VEGFA (D) by cluster. Kruskal-Wallis test  
494 performed comparing analyte levels between clusters. \*\*:  $p \leq 0.01$ ; \*\*\*:  $p \leq 0.001$ ; \*\*\*\*:  $p \leq 0.0001$


495


496

**Cluster 2**





**Cluster 3**

**Cluster 1**





● Died ▲ ICU ■ Inpatient + Outpatient



**Table 1.** Baseline demographics across TDA clusters.

<b>Characteristic</b>	<b>Total (N=129)</b>	<b>Cluster 1 (N=50)</b>	<b>Cluster 2 (N=64)</b>	<b>Cluster 3 (N=15)</b>	<b>p-value</b>
<b>Male gender — no. (%)</b>	86(66.7%)	31(62%)	41(64.1%)	14(93.3%)	0.06†
<b>Age — years, median (IQR)</b>	41.3 (30.1, 56)	51.8 (37.3, 65)	37.1 (28.05, 49.55)	36.3 (24.6, 55.2)	<0.001‡
<b>Race or ethnic group — no. (%)</b>					0.01†
White	81 (62.8)	30 (60.0)	43 (67.2)	8 (53.3)	
Black	31 (24.0)	16 (32.0)	12 (18.8)	3 (20.0)	
Other	6 (4.7)	1 (2.0)	5 (7.8)	2 (13.3)	
Asian	5 (3.9)	0 (0)	3 (4.7)	2 (13.3)	
Native American	3 (2.3)	0 (0)	1 (1.6)	0 (0)	
Native Hawaiian	3 (2.3)	3 (6.0)	0 (0)	0 (0)	
<b>Ethnicity — no. (%)</b>					0.88†
Hispanic or Latinx	31(24)	13(26)	15(23.4)	3(20)	
<b>Charlson Comorbidity Index (CCI) — median (IQR)</b>	0 (0, 2)	2 (2, 3)	0 (0, 0.5)	0 (0, 1)	0.009‡
<b>Body mass index — kg/m<sup>2</sup>, median (IQR)</b>	30 (27, 34)	33.5 (29, 37)	28 (25, 31)	28 (25, 31)	<0.001‡
<b>Days post-symptom onset — median (IQR)</b>	21.0 (18.0, 25.0)	20 (17.0, 25.0)	21.0 (19.0, 25.5)	22.0 (21.0, 25.0)	0.16‡
<b>Hospitalization at Timepoint — no. (%)</b>					<0.001
ICU	10(7.8)	9(18)	1(1.6)	0	
Inpatient	28(21.7)	16(32)	7(10.9)	5(33.3)	
Outpatient	91(70.5)	25(50)	56(87.5)	10(66.7)	
<b>Peak severity — no. (%)</b>					<0.001
Death	5 (3.9)	5 (10.0)	0 (0)	0 (0)	
ICU	16 (12.4)	10 (20.0)	3 (4.7)	3 (20.0)	
Inpatient	31 (24.0)	18 (36.0)	9 (14.1)	4 (26.7)	
Outpatient	77 (59.7)	17 (34.0)	52 (81.3)	8 (53.3)	
<b>Systemic Steroid use — no. (%)</b>	5 (3.9)	5 (10.0)	0 (0)	0 (0)	

\*All categorical variables are presented as N (%) and continuous variable

† Chi-square test

‡ Mann Whitney U test

|| Fischer's Exact test

**Table 2.** Comparison of the Ella biomarkers across TDA clusters. For each subject, one sample was selected based on highest coefficient of variation.

Variable	Plasma log <sub>10</sub> pg/mg, median (IQR)				p-value*
	Total	Cluster 1	Cluster 2	Cluster 3	
<b>CRP</b>	6.75 (6.09, 7.62)	7.33 (6.67, 7.98)	6.43 (5.89, 7.11)	6.29 (5.68, 7.13)	<b>&lt;0.001</b>
<b>CXCL10</b>	2.17 (1.95, 2.37)	2.28 (1.94, 2.53)	2.1 (1.88, 2.28)	2.19 (2.09, 2.51)	<b>0.02</b>
<b>D-dimer</b>	5.69 (5.34, 6.23)	6.06 (5.68, 6.85)	5.49 (5.27, 5.87)	5.68 (5.3, 6.52)	<b>&lt;0.001</b>
<b>Ferritin</b>	5.3 (4.98, 5.65)	5.46 (5.07, 5.87)	5.17 (4.82, 5.37)	5.51 (5.31, 5.9)	<b>&lt;0.001</b>
<b>IFN<math>\gamma</math></b>	-0.25 (-0.45, 0)	-0.3 (-0.58, 0)	-0.21 (-0.39, 0)	-0.27 (-0.46, 0.02)	0.11
<b>IL1Ra</b>	2.85 (2.56, 3.11)	3.01 (2.84, 3.37)	2.67 (2.5, 2.97)	2.69 (2.4, 2.92)	<b>&lt;0.001</b>
<b>IL5</b>	-0.56 (-0.86, 0.34)	-0.57 (-0.95, -0.4)	-0.57 (-0.81, -0.31)	-0.51 (-0.85, -0.24)	0.69
<b>IL6</b>	0.26 (0.01, 0.63)	0.52 (0.24, 1.1)	0.07 (-0.13, 0.43)	0.26 (0.05, 0.6)	<b>&lt;0.001</b>
<b>Procalcitonin</b>	1.78 (1.63, 2)	1.92 (1.7, 2.25)	1.69 (1.59, 1.86)	1.92 (1.77, 2.1)	<b>&lt;0.001</b>
<b>RAGE</b>	2.93 (2.78, 3.04)	2.76 (2.58, 2.87)	3.02 (2.92, 3.09)	3 (2.8, 3.07)	<b>&lt;0.001</b>
<b>TNFR1</b>	3.03 (2.95, 3.18)	3.15 (3.01, 3.3)	2.98 (2.91, 3.08)	3.04 (2.97, 3.16)	<b>&lt;0.001</b>
<b>VEGFA</b>	1.64 (1.43, 1.92)	1.9 (1.57, 2.12)	1.58 (1.43, 1.76)	1.25 (0.8, 1.52)	<b>&lt;0.001</b>

\*Distributions among all clusters compared using a Kruskal-Wallis test.